
## Linda Sofie Lindström

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6091320/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. JAMA Oncology, 2017, 3, 1503.	7.1	91
2	Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Research and Treatment, 2016, 160, 131-143.	2.5	82
3	Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 726-733.	6.3	55
4	The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. Breast Cancer Research, 2019, 21, 34.	5.0	48
5	Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. Clinical Cancer Research, 2017, 23, 7512-7520.	7.0	43
6	Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. JAMA Oncology, 2019, 5, 1304.	7.1	33
7	Breast cancer in young women and prognosis: How important are proliferation markers?. European Journal of Cancer, 2017, 84, 278-289.	2.8	24
8	Multiâ€level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients. Molecular Oncology, 2014, 8, 741-752.	4.6	23
9	A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels. Oncogene, 2020, 39, 5430-5440.	5.9	23
10	Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. Molecular Oncology, 2016, 10, 517-525.	4.6	21
11	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clinical Cancer Research, 2017, 23, 7225-7231.	7.0	17
12	Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Research and Treatment, 2017, 166, 593-601.	2.5	17
13	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	12.8	16
14	Differences in survival for patients with familial and sporadic cancer. International Journal of Cancer, 2017, 140, 581-590.	5.1	16
15	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. Clinical Cancer Research, 2017, 23, 2584-2592.	7.0	15
16	Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Network Open, 2021, 4, e2114716.	5.9	14
17	Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. Molecular Oncology, 2015, 9, 1384-1391.	4.6	13
18	Cause-specific mortality in women with breast cancer <i>in situ</i> . International Journal of Cancer, 2017, 140, 2414-2421.	5.1	13

## Linda Sofie Lindström

#	Article	IF	CITATIONS
19	Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ <i>ERBB2</i> -Negative Breast Cancer Treated With and Without Tamoxifen Therapy. JAMA Network Open, 2021, 4, e2114904.	5.9	12
20	Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa087.	2.9	11
21	Site-specific familial risk and survival of familial and sporadic head and neck cancer. International Journal of Cancer, 2017, 141, 497-502.	5.1	10
22	An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. Clinical Cancer Research, 2016, 22, 2417-2426.	7.0	8
23	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. Npj Breast Cancer, 2021, 7, 2.	5.2	7
24	Clinical and molecular characteristics of estrogen receptorâ€positive ultralow risk breast cancer tumors identified by the 70â€gene signature. International Journal of Cancer, 2022, 150, 2072-2082.	5.1	7
25	Sequential metastatic biopsies and functional imaging in breast cancer Journal of Clinical Oncology, 2014, 32, e22120-e22120.	1.6	0
26	There is more to the picture than meets the eye: Population-based study on biopsy verification of suspected breast cancer recurrences Journal of Clinical Oncology, 2015, 33, 542-542.	1.6	0
27	Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer Journal of Clinical Oncology, 2015, 33, e22090-e22090.	1.6	0
28	Gene expression of metastatic biopsies for prediction of response to palliative chemotherapy in breast cancer Journal of Clinical Oncology, 2015, 33, 1044-1044.	1.6	0